Introduction: the acute kidney injury is one of the main complications of SARs-Cov-2 infection. Objective: identify the COVID-19 prevalence and kidney damage of evaluated patients followed up by nephrology team in an intensive care unit. Materials and Methods: adults and elderly people of both genders followed up by the nephrology team and performed the RT PCR test for COVID were included on this study. For analysis and comparison, the patients were divided in RTP PCR positive and negative groups. To assess the kidney damage impact on death rates another analysis was performed considering the death or the absence of death as outcome. Results: the prevalence of COVID-19 was 58.5% and the prevalence of AKI was 75.0% among the 176 patients. More than half of patients (55.2%) undergoing renal replacement therapy tested positive for COVID-19. On the evaluation of Charlson Comorbidity Index was identified statistically significant difference in the proportions of the negative and positive COVID-19 groups in scores 0, 1 and 2. The second analysis identified a significant association between kidney disease and death in the ICU (p lt; 0.05). Patients with CKD died less 13/98 (13.3%) when compared to those with AKI 85/98 (86.7%). When they had both COVID-19 and AKI, the mortality rate was 69.0%. Conclusion: the prevalence of COVID-19 in patients undergoing intensive care during the first semester of 2021 was higher than 50% and the AKI prevalence in patients tested positive for COVID-19 was higher than 80%. The death rates among the patients with AKI and COVID-19 simultaneously were upper than 60%.

Introdução: entre as principais complicações da infecção do SARs-Cov-2 está a Insuficiência renal aguda. Objetivo: identificar a prevalência de COVID-19 e acometimento renal em pacientes avaliados e acompanhados pela equipe de nefrologia em centro de tratamento intensivo. Material e Métodos: participaram adultos e idosos de ambos os sexos acompanhados pela equipe de nefrologia e que realizaram o teste RT PCR para COVID. Para análise e comparação os pacientes foram agrupados em RTP PCR positivo e negativo. Para avaliar o impacto do acometimento renal nas taxas de óbito outra análise foi realizada considerando como desfecho evolução a óbito ou não. Resultados: incluídos 176 pacientes sendo a prevalência de COVID-19 58,5% e IRA 75%. Dos pacientes que realizaram Terapia Renal Substitutiva, mais da metade (55,2%) tinham COVID 19 +. O índice de Charlson identificou-se diferença estatisticamente significativa nas proporções dos grupos COVID-19 negativo e positivo nos índices 0, 1 e 2. A segunda análise identificou associação significativa entre doença renal e óbito no CTI (p lt; 0,05). Os pacientes com DRC evoluíram menos a óbito 13/98 (13,3%) quando comparados com aqueles com IRA 85/98 (86,7%). E quando tinham simultaneamente o COVID 19 e a IRA a taxa de mortalidade foi de 69,0%. Conclusão: A prevalência da COVID-19 em pacientes internados no CTI adulto durante o primeiro semestre de 2021 foi acima de 50% e a prevalência de IRA nos pacientes positivos ultrapassou a marca dos 80%. nbsp;A taxa de óbito entre os pacientes com IRA e COVID 19 + simultâneos ultrapassou 60%.

Abstract Evidence on factors associated with the progression of chronic kidney disease (CKD) is still under construction. The present study aimed to evaluate sociodemographic, clinical, and drug use factors associated with the progression of CKD. A retrospective cohort study was conducted with 193 patients with CKD stages 3A to 5- non-dialysis followed for three years in a Brazilian city. The outcome was the evolution to renal replacement therapy (RRT) or death. A total of 52.3 % (n = 101) were men and 83.4 % (n = 161) elderly. The median age was 72.0 years, and 22.3 % (n = 44) progressed to RRT or death, and the three-year mortality rate was 20.2 %. Participants exposed to angiotensin converting enzyme inhibitors or angiotensin II receptor blockers had a lower risk of progressing to the outcome (hazard ratio (HR) 0.25; p = 0.003) and higher survival (p = 0.022) when compared to those not exposed to these drugs. Age (HR 1.06;) and use of omeprazole (HR 6.25; CI; p <0.01) and hydrochlorothiazide (HR 2.80; p = 0.028) increased the risks of RRT or death. The results highlight the importance of rational management of pharmacotherapy for patients with CKD.